[go: up one dir, main page]

CO2017005538A2 - Chimeric anti-cldn antigen receptors - Google Patents

Chimeric anti-cldn antigen receptors

Info

Publication number
CO2017005538A2
CO2017005538A2 CONC2017/0005538A CO2017005538A CO2017005538A2 CO 2017005538 A2 CO2017005538 A2 CO 2017005538A2 CO 2017005538 A CO2017005538 A CO 2017005538A CO 2017005538 A2 CO2017005538 A2 CO 2017005538A2
Authority
CO
Colombia
Prior art keywords
chimeric anti
antigen receptors
cldn
cldn antigen
receptors
Prior art date
Application number
CONC2017/0005538A
Other languages
Spanish (es)
Inventor
David Liu
Scott J Dylla
Robert A Stull
Paul Anthony Escarpe
Original Assignee
Abbvie Stemcentrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2014/064165 external-priority patent/WO2015069794A2/en
Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc
Publication of CO2017005538A2 publication Critical patent/CO2017005538A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se proporcionan nuevos receptores quiméricos de antígeno anti–CLDN y métodos de uso de los mismos para tratar trastornos proliferativos.Provided herein are new chimeric anti-CLDN antigen receptors and methods of using the same to treat proliferative disorders.

CONC2017/0005538A 2014-11-05 2017-06-02 Chimeric anti-cldn antigen receptors CO2017005538A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US2014/064165 WO2015069794A2 (en) 2013-11-06 2014-11-05 Novel anti-claudin antibodies and methods of use
US201562157928P 2015-05-06 2015-05-06
US201562247108P 2015-10-27 2015-10-27
PCT/US2015/059106 WO2016073649A1 (en) 2014-11-05 2015-11-04 Anti-cldn chimeric antigen receptors and methods of use

Publications (1)

Publication Number Publication Date
CO2017005538A2 true CO2017005538A2 (en) 2017-10-10

Family

ID=55909771

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0005538A CO2017005538A2 (en) 2014-11-05 2017-06-02 Chimeric anti-cldn antigen receptors

Country Status (23)

Country Link
US (1) US20170334991A1 (en)
EP (1) EP3215523A4 (en)
JP (1) JP2017535283A (en)
KR (1) KR20170085531A (en)
CN (1) CN107207580A (en)
AU (1) AU2015343079A1 (en)
BR (1) BR112017009517A2 (en)
CA (1) CA2966618A1 (en)
CL (1) CL2017001118A1 (en)
CO (1) CO2017005538A2 (en)
CR (1) CR20170235A (en)
DO (1) DOP2017000110A (en)
EA (1) EA201790967A1 (en)
EC (1) ECSP17031725A (en)
IL (1) IL252090A0 (en)
MA (1) MA40921A (en)
MX (1) MX2017005797A (en)
PE (1) PE20171060A1 (en)
PH (1) PH12017500825A1 (en)
SG (1) SG11201703669YA (en)
TW (1) TW201625677A (en)
WO (1) WO2016073649A1 (en)
ZA (1) ZA201703471B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011009632A (en) 2009-03-30 2011-10-19 Eisai R&D Man Co Ltd Liposome composition.
JP6515111B2 (en) * 2013-11-06 2019-05-22 アッヴィ・ステムセントルクス・エル・エル・シー Novel anti-claudin antibodies and methods of use
US12029724B2 (en) 2016-04-28 2024-07-09 Eisai R&D Management Co., Ltd. Method for inhibiting tumor growth
KR20190082782A (en) * 2016-10-14 2019-07-10 머크 샤프 앤드 돔 코포레이션 A combination of PD-1 antagonist and eribulin for the treatment of urinary tract carcinoma
CN116999572A (en) 2017-09-29 2023-11-07 第一三共株式会社 Antibody-drug conjugates, pharmaceutical compositions and their applications in preparing drugs for treating tumors
WO2020051562A2 (en) 2018-09-07 2020-03-12 Beam Therapeutics Inc. Compositions and methods for improving base editing
WO2020114518A1 (en) * 2018-12-07 2020-06-11 科济生物医药（上海）有限公司 Tumor combined immunotherapy
KR20210126008A (en) * 2019-01-07 2021-10-19 카르스젠 테라퓨틱스 컴퍼니, 리미티드 Combination of Cellular Immunotherapy
MX2021009507A (en) * 2019-02-08 2021-09-08 Biontech Cell & Gene Therapies Gmbh CELLS MODIFIED BY CHIMERIC ANTIGEN RECEPTOR FOR THE TREATMENT OF CANCERS THAT EXPRESS CLDN6.
WO2020205759A1 (en) * 2019-03-29 2020-10-08 Pact Pharma, Inc. Personalized neoantigen-specific adoptive cell therapies
CA3138414A1 (en) 2019-05-16 2020-11-19 Qilu Pharmaceutical Co., Ltd. Antibodyagainst claudin 18a2 and use thereof
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
WO2021129927A1 (en) * 2019-12-23 2021-07-01 Biontech Cell & Gene Therapies Gmbh Treatment with immune effector cells engineered to express an antigen receptor
CN113637082A (en) * 2020-04-27 2021-11-12 启愈生物技术(上海)有限公司 Bispecific antibody targeting human claudin and human PDL1 protein and application thereof
US20210347847A1 (en) * 2020-05-11 2021-11-11 The Broad Institute, Inc. Therapeutic targeting of malignant cells using tumor markers
JP2024500847A (en) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド Chimeric antigen receptor systems with compatible receptor specificities
KR20230154317A (en) * 2021-03-05 2023-11-07 상하이 젠베이스 바이오테크놀로지 씨오., 엘티디. Anti-CLDN6 antibodies and uses thereof
CN114478802B (en) * 2022-01-28 2023-05-26 郑州大学 Chimeric antigen receptor and application thereof
CN115991770A (en) * 2022-05-11 2023-04-21 迈威(上海)生物科技股份有限公司 Anti-human GAS6 antibodies or antigen binding fragments thereof and uses thereof
WO2024088325A1 (en) * 2022-10-25 2024-05-02 科济生物医药（上海）有限公司 Antibody and use thereof
CN117169518B (en) * 2023-11-03 2024-01-19 赛德特(北京)生物工程有限公司 Method and kit for detecting CD3 antibody residues in T lymphocyte preparation
WO2025209525A1 (en) * 2024-04-03 2025-10-09 江苏恒瑞医药股份有限公司 Anti-cldn6 antibody, antibody-drug conjugate comprising same and medical use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101074261A (en) * 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 TRAIL receptor I and/or TRAIL receptor 2 specific antibody and its use
WO2008105560A1 (en) * 2007-02-27 2008-09-04 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-grp78 antibody as active ingredient
EP3064512B1 (en) * 2008-01-11 2023-08-30 The University of Tokyo Anti-cldn6 antibody
NO2499161T3 (en) * 2009-11-11 2018-02-03
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
EP3623380B1 (en) * 2013-03-15 2025-10-22 Novartis AG Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
JP6515111B2 (en) * 2013-11-06 2019-05-22 アッヴィ・ステムセントルクス・エル・エル・シー Novel anti-claudin antibodies and methods of use
AU2015239683B2 (en) * 2014-04-01 2019-08-22 Astellas Pharma Inc. Claudin-6-Specific immunoreceptors and T cell epitopes
WO2016180467A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
HK1254743A1 (en) * 2015-12-04 2019-07-26 Abbvie Stemcentrx Llc Novel anti-claudin antibodies and methods of use

Also Published As

Publication number Publication date
MA40921A (en) 2017-09-12
MX2017005797A (en) 2017-10-23
US20170334991A1 (en) 2017-11-23
WO2016073649A1 (en) 2016-05-12
BR112017009517A2 (en) 2017-12-19
DOP2017000110A (en) 2017-05-31
AU2015343079A1 (en) 2017-05-25
CR20170235A (en) 2017-07-21
JP2017535283A (en) 2017-11-30
EP3215523A1 (en) 2017-09-13
KR20170085531A (en) 2017-07-24
PE20171060A1 (en) 2017-07-21
CN107207580A (en) 2017-09-26
PH12017500825A1 (en) 2017-10-18
ZA201703471B (en) 2019-06-26
SG11201703669YA (en) 2017-06-29
CA2966618A1 (en) 2016-05-12
CL2017001118A1 (en) 2018-01-05
EA201790967A1 (en) 2017-10-31
TW201625677A (en) 2016-07-16
IL252090A0 (en) 2017-07-31
ECSP17031725A (en) 2017-06-30
EP3215523A4 (en) 2018-06-20

Similar Documents

Publication Publication Date Title
CO2017005538A2 (en) Chimeric anti-cldn antigen receptors
BR112017017927A2 (en) chimeric anti-dll3 antigen receptors and methods of use
CR20160500A (en) ANTI-OX40 ANTIBODIES AND METHODS OF USE
CL2018000595A1 (en) Anti-PD1 antibodies and methods of use
MX2023005880A (en) Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use.
BR112017013176A2 (en) chimeric antigen receptors and methods for using them
PE20181005A1 (en) BISPECIFIC ANTIBODIES AGAINST THE HUMAN A- BETA AND THE HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USE
CL2017000545A1 (en) Anti-her2 and immunoconjugate antibodies
MX2017007049A (en) ANTI-CD79B ANTIBODIES AND METHODS OF USE.
MX374788B (en) ANTI-TIM3 ANTIBODIES AND METHODS OF USE.
CL2018001481A1 (en) New anti-claudin antibodies and their methods of use
MX2016010433A (en) ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE.
CL2015002357A1 (en) New antibody conjugates and uses thereof
MX2016014247A (en) Anti-ptk7 antibody-drug conjugates.
DOP2017000052A (en) NEW ANTI-MFI2 ANTIBODIES AND METHODS OF USE
CO2018007236A2 (en) CFR regulators and methods of use
BR112017006916A2 (en) use of canthaxanthin for laying hens.
HK1243090A1 (en) Anti-cldn chimeric antigen receptors and methods of use